Dr. Jacqueline O'Leary began her pursuit of research as an undergraduate at Stanford investigating drug development, continued at UCSF where she received and MD with thesis for work in cellular and molecular biology. Following her internal medicine residency at UT Southwestern in Dallas, Dr. O'Leary did a GI fellowship and transplant Hepatology fellowship at Massachusetts General Hospital. Her post-doctoral research at Harvard focused on immunology. Afterward, she completed a Master's in Public Health from the Harvard School of Public Health.

I am a board-certified Pediatric Gastroenterologist and Transplant Hepatologist and Section Chief of Hepatology and Transplant Medicine at Children's Mercy Hospital in Kansas City. I have a strong interest in translational research related to liver disease and transplantation, and novel therapeutics to treat disordered inflammation in the liver. My background in the lab includes basic research in dendritic cell biology, antigen presentation and cell-based immunotherapy.

Dr Lewindon is a senior paediatric gastroenterologist and hepatologist at the Queensland Children's Hospital in Brisbane Australia, the sole tertiary paediatric hospital for the state. Born, studied and trained in the UK, then trained in Australia he has practiced subspeciality gastroenterology including motility, cystic fibrosis, liver transplantation, eosinophilic oesophagitis before establishing the paediatric IBD service in Queensland where he is still clinical lead.

I am a physician scientist and pediatric transplant hepatologist at Northwestern Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago. My research focuses on basic and translational studies investigating the unfolded protein response (UPR) in murine models of cholestatic liver disease and pediatric cholestatic liver diseases.

Mohammad Almeqdadi, MD, is a transplant hepatologist and gastroenterologist at Tufts Medical Center in Boston. His clinical work focuses on advanced liver disease, liver transplantation, portal hypertension, and gastrointestinal care for complex patients. He is also involved in clinical research, quality improvement, and medical education, with an interest in using EHR tools, data-driven workflows, and practical automation to improve efficiency, patient care, and clinician experience.

I am a Hepatologist and Senior Clinical and Research Consultant at the Liver Disease and Hepatitis Program at the Alaska Native Medical Center in Anchorage, Alaska., an auxiliary professor at University of Alaska Health Sciences Program and Clinical Professor of Medicine at the University of Washington. I have directed the vaccination programs in Alaska Natives that reduced the prevalence of hepatitis B from the highest in the US to the lowest in the world.

Matthew D'Uva is the Chief Executive Officer (CEO) of the American Association for the Study of Liver Diseases (AASLD), the premier organization of health care professionals, researchers, and scientists committed to preventing and curing liver disease worldwide. Matthew also serves as CEO of AASLD Foundation, the philanthropic arm of AASLD committed to developing and supporting the hepatology workforce of the future.

In his role, Matthew oversees the implementation of AASLD's strategic plan, management of the organization's operations, and a team of nearly 50 professionals.

Director, The Autoimmune and Rare Liver Disease Programme, and the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Division of Gastroenterology and Hepatology, Toronto General Hospital, Canada

Dr. Trivedi is full professor at the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC) in the UK. He is Chief Investigator for the UK-Primary Sclerosing Cholangitis (PSC) consortium, elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated and cholestatic liver disease, and steering committee member of the Global Primary Biliary Cholangitis (PBC) Group and International PSC Study Groups in 2022.